[
  {
    "item_id": "press_corporate__medincell_20260204_516562",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults",
    "content": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in AdultsDecember 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:c2ed94aa0c2dfe5546577b2452e9dc35255e76491c079fb1906d579722fa5fd2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 33
    },
    "normalized_at": "2026-02-04T16:24:25.394201Z",
    "effective_date": "2025-12-09",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-12-09",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Teva Pharmaceuticals, a partner of Medincell, announced the submission of a New Drug Application to the U.S. FDA for an olanzapine extended-release injectable suspension (TEV-'749 / mdc-TJK) for the once-monthly treatment of schizophrenia in adults.",
      "entities": {
        "companies": [
          "Medincell",
          "Teva Pharmaceuticals"
        ],
        "molecules": [
          "olanzapine"
        ],
        "technologies": [
          "extended-release injectable suspension"
        ],
        "trademarks": [
          "TEV-'749",
          "mdc-TJK"
        ],
        "indications": [
          "schizophrenia"
        ],
        "dosing_intervals": [
          "once-monthly"
        ]
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2025-12-09",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 90,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "core_technologies: extended-release injectable suspension",
          "trademarks: TEV-'749, mdc-TJK"
        ],
        "medium": [
          "technology_families: extended-release",
          "dosing_intervals: once-monthly",
          "hybrid_companies: Teva Pharmaceuticals"
        ],
        "weak": [
          "molecules: olanzapine"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "core_technologies": 20,
          "trademarks": 15,
          "hybrid_companies": 10,
          "technology_families": 5,
          "dosing_intervals": 5
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 90
      },
      "reasoning": "The item mentions core LAI technologies (extended-release injectable suspension), trademarks, dosing interval, and a hybrid company partner. Multiple strong and medium signals indicate high relevance to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5,
        "regulatory_tech_combo": 1.0
      },
      "penalties": {},
      "final_score": 3.8,
      "effective_date": "2025-12-09",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.82,
        "weighted_base": 0.29,
        "total_bonus": 3.5,
        "total_penalty": 0,
        "raw_score": 3.79,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260204_6f822c",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "content": "10 December, 2025Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based productsThe agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.READ MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:52.534202",
    "language": "en",
    "content_hash": "sha256:d9b83fe6cb94dcaa8e1245f54fd2e589b6cf48151c4b60378d8012a5e5a20125",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 61
    },
    "normalized_at": "2026-02-04T16:26:19.905465Z",
    "effective_date": "2025-12-10",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-12-10",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell® technology. Nanexa will receive an upfront payment of $3 million and is eligible for up to $500 million in potential milestone payments and royalties.",
      "entities": {
        "companies": [
          "Nanexa",
          "Moderna"
        ],
        "molecules": [],
        "technologies": [
          "PharmaShell®"
        ],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2025-12-10",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 90,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "core_technologies",
          "pure_player_companies",
          "trademarks"
        ],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 70,
        "entity_boosts": {
          "pure_player_company": 10,
          "trademark": 10
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 90
      },
      "reasoning": "The item mentions the pure player company Nanexa, their core PharmaShell® technology which is a trademark, and a partnership event with Moderna. Multiple strong signals indicate high relevance to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0
      },
      "penalties": {},
      "final_score": 3.3,
      "effective_date": "2025-12-10",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.82,
        "weighted_base": 0.33,
        "total_bonus": 3.0,
        "total_penalty": 0,
        "raw_score": 3.33,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260204_150759",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "content": "Medincell Awarded New Grant to Fight MalariaNovember 24, 2025November 24, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:2077438074167cf84530cd63f435d4d32c7966446ec74b1d2d88da3c63b8e447",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2026-02-04T16:24:30.676448Z",
    "effective_date": "2025-11-24",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-24",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Medincell was awarded a new grant to fund research efforts to fight malaria. The grant amount and details were not provided.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "malaria"
        ],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-24",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 65,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [
          "indication: malaria"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "company": 5
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 65
      },
      "reasoning": "The item mentions Medincell receiving a grant to research malaria treatments, which is a relevant indication for LAI therapies. However, no specific LAI technologies or products are mentioned, resulting in a medium confidence match with a moderate score."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0
      },
      "penalties": {
        "aging_penalty": -0.5
      },
      "final_score": 2.8,
      "effective_date": "2025-11-24",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.3,
        "total_bonus": 3.0,
        "total_penalty": -0.5,
        "raw_score": 2.8,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__camurus_20260204_1e8bef",
    "source_key": "press_corporate__camurus",
    "source_type": "press_corporate",
    "title": "09 January 2026RegulatoryCamurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly",
    "content": "202609 January 2026RegulatoryCamurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly202530 December 2025RegulatoryChange in number of shares and votes in Camurus16 December 2025Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism28 November 2025RegulatoryChange in number of shares and votes in Camurus13 November 2025RegulatoryCamurus’ Nomination Committee appointed for the Annual Gene",
    "url": "https://www.camurus.com/media/press-releases/2026/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiz-for-the-treatment-of-acromegaly/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:58.248133",
    "language": "en",
    "content_hash": "sha256:f8e7b48eaf463948ffc29e9644ba84039abc68b77b343066cf28caad398323e4",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 63
    },
    "normalized_at": "2026-02-04T16:27:01.383312Z",
    "effective_date": "2026-01-09",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-09",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Camurus announced that the FDA has accepted the resubmission of their New Drug Application (NDA) for Oclaiz™, a treatment for acromegaly.",
      "entities": {
        "companies": [
          "Camurus"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [
          "Oclaiz™"
        ],
        "indications": [
          "acromegaly"
        ],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-09",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "pure_player_company: Camurus",
          "trademark: Oclaiz™"
        ],
        "medium": [],
        "weak": [
          "indication: acromegaly"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "pure_player_company": 25,
          "trademark": 20
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "The item mentions the pure player company Camurus and their trademark product Oclaiz™ for treatment of acromegaly. This is a regulatory event related to an LAI product, so it is highly relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5
      },
      "penalties": {},
      "final_score": 2.8,
      "effective_date": "2026-01-09",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.88,
        "weighted_base": 0.31,
        "total_bonus": 2.5,
        "total_penalty": 0,
        "raw_score": 2.81,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260204_c147c4",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "content": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025November 5, 2025November 5, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:7f3a6a00314b234fd43355bd5206916bed56d46d3f812a774fb1cbb61c28ec28",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 22
    },
    "normalized_at": "2026-02-04T16:24:47.082435Z",
    "effective_date": "2025-11-05",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-05",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Teva is preparing to submit a New Drug Application (NDA) for an olanzapine long-acting injectable (LAI) formulation to the US FDA in Q4 2025. UZEDY®, a product of Teva, continues to show strong growth.",
      "entities": {
        "companies": [
          "Teva"
        ],
        "molecules": [
          "olanzapine"
        ],
        "technologies": [
          "LAI"
        ],
        "trademarks": [
          "UZEDY®"
        ],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-05",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 90,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "core_technologies: LAI",
          "pure_player_companies: Teva",
          "trademarks: UZEDY®"
        ],
        "medium": [],
        "weak": [
          "molecules: olanzapine"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 70,
        "entity_boosts": {
          "core_technologies": 20,
          "pure_player_companies": 15,
          "trademarks": 10
        },
        "recency_boost": 5,
        "confidence_penalty": 0,
        "total": 90
      },
      "reasoning": "The item mentions a long-acting injectable (LAI) formulation of olanzapine by Teva, a pure-play pharma company, and their trademarked product UZEDY®. The regulatory event of an upcoming NDA submission is highly relevant to the LAI domain. Strong signals and a recent date result in a high confidence, high scoring match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5,
        "regulatory_tech_combo": 1.0
      },
      "penalties": {
        "old_penalty": -1.0
      },
      "final_score": 2.7,
      "effective_date": "2025-11-05",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.65,
        "weighted_base": 0.23,
        "total_bonus": 3.5,
        "total_penalty": -1.0,
        "raw_score": 2.73,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercebiotech_20260204_8d1e08",
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/wave-regains-rights-genetic-disease-rna-editor-gsk\" hreflang=\"en\">GSK gives back rights to Wave's genetic disease RNA editor</a>",
    "content": "Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not to take over development of WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency (AATD), with Massachusetts-based Wave reclaiming full rights and planning to seek accelerated approval for the asset from the FDA.",
    "url": "https://www.fiercebiotech.com/biotech/wave-regains-rights-genetic-disease-rna-editor-gsk",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:46.719869",
    "language": "en",
    "content_hash": "sha256:05cdfb808f57707b6c5d79a02f2433a7a7f256f5e155879ffb63848f83d8a49c",
    "metadata": {
      "author": "Darren Incorvaia",
      "tags": [],
      "word_count": 53
    },
    "normalized_at": "2026-02-04T16:25:29.233599Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.8,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Wave Life Sciences has regained full rights to its lead RNA editing candidate WVE-006 for alpha-1 antitrypsin deficiency (AATD) from GSK. Wave plans to seek accelerated approval for WVE-006 from the FDA.",
      "entities": {
        "companies": [
          "Wave Life Sciences",
          "GSK"
        ],
        "molecules": [
          "WVE-006"
        ],
        "technologies": [
          "RNA editing",
          "oligonucleotide"
        ],
        "trademarks": [],
        "indications": [
          "alpha-1 antitrypsin deficiency (AATD)"
        ],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.8,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "pure_player_company: Wave Life Sciences"
        ],
        "medium": [
          "technology_family: RNA editing"
        ],
        "weak": [
          "molecule: WVE-006"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "pure_player_company": 25,
          "technology_family": 15,
          "molecule": 5
        },
        "recency_boost": 5,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "Wave Life Sciences is a pure-play LAI company working on RNA editing technology, with a lead candidate WVE-006 for a genetic disease. Recent partnership event with GSK. High confidence LAI match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0,
        "partnership_molecule_combo": 1.5
      },
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 2.7,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.2,
        "total_bonus": 4.5,
        "total_penalty": -2.0,
        "raw_score": 2.7,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260203_98ac34",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?",
    "content": "Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on ...",
    "url": "https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-04T16:23:49.403328",
    "language": "en",
    "content_hash": "sha256:b59ea9fed19752aba81801f3f3b9a56fabd3e1451dd5abe0c3071bf640c3ac4d",
    "metadata": {
      "author": "Elizabeth Cairns",
      "tags": [
        "R&D"
      ],
      "word_count": 33
    },
    "normalized_at": "2026-02-04T16:25:53.590056Z",
    "effective_date": "2026-02-03",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": "2023-05-23",
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Pfizer reported that a monthly injection from its $10 billion acquisition of Metsera helped obesity patients lose up to 10.5% of their weight. The article does not mention dosing intervals or long-acting injectable technologies.",
      "entities": {
        "companies": [
          "Pfizer",
          "Metsera"
        ],
        "molecules": [
          "GLP-1"
        ],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "obesity"
        ],
        "dosing_intervals": [
          "monthly"
        ]
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-23",
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 60,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "dosing_intervals: monthly"
        ],
        "weak": [
          "molecules: GLP-1"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "dosing_interval": 10
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 60
      },
      "reasoning": "The item mentions a monthly dosing interval for a GLP-1 injectable product, which are medium and weak signals for LAI relevance respectively. No strong signals or exclusions detected. Moderately confident LAI match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {},
      "final_score": 2.3,
      "effective_date": "2026-02-03",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.3,
        "total_bonus": 2.0,
        "total_penalty": 0,
        "raw_score": 2.3,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260204_4ce385",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation",
    "content": "PRESSRELEASES27 January, 2026Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide FormulationNanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.Read moreREAD MORE10 December, 2025Nanexa and Moderna enter into license and option agreement for",
    "url": "https://nanexa.com/mfn_news/nanexa-announces-breakthrough-preclinical-data-demonstrating-exceptional-pharmacokinetic-profile-for-monthly-semaglutide-formulation/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:52.534202",
    "language": "en",
    "content_hash": "sha256:afea17df7bd4fa6526d533e909def01570a7b73dbc6cf35af9ab3980f53efc10",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 55
    },
    "normalized_at": "2026-02-04T16:26:06.630406Z",
    "effective_date": "2026-01-27",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-27",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Nanexa announced preclinical data showing its PharmaShell® atomic layer deposition platform improved the pharmacokinetic profile of monthly semaglutide injections, potentially mitigating side effects of GLP-1 drugs.",
      "entities": {
        "companies": [
          "Nanexa"
        ],
        "molecules": [
          "semaglutide"
        ],
        "technologies": [
          "atomic layer deposition",
          "PharmaShell®"
        ],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": [],
        "dosing_intervals": [
          "monthly"
        ]
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-27",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "core_technologies: atomic layer deposition",
          "pure_player_companies: Nanexa",
          "trademarks: PharmaShell®"
        ],
        "medium": [
          "technology_families: drug delivery",
          "dosing_intervals: monthly"
        ],
        "weak": [
          "molecules: semaglutide"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "core_technologies": 10,
          "pure_player_companies": 10,
          "trademarks": 10
        },
        "recency_boost": 10,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "The item mentions Nanexa's core atomic layer deposition technology (PharmaShell®) applied to improve the pharmacokinetics of a monthly semaglutide formulation, which is highly relevant to the LAI domain. Multiple strong and medium signals detected with no exclusions."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {},
      "final_score": 2.3,
      "effective_date": "2026-01-27",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.92,
        "weighted_base": 0.28,
        "total_bonus": 2.0,
        "total_penalty": 0,
        "raw_score": 2.28,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260204_4ce385",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation",
    "content": "27 January, 2026Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide FormulationNanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.Read moreREAD MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-announces-breakthrough-preclinical-data-demonstrating-exceptional-pharmacokinetic-profile-for-monthly-semaglutide-formulation/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:52.534202",
    "language": "en",
    "content_hash": "sha256:487400f57c4245d14b4bdbc629d08024146dadfef92fcb771eb0ffefe5e0401c",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 44
    },
    "normalized_at": "2026-02-04T16:26:13.624843Z",
    "effective_date": "2026-01-27",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-27",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Nanexa announced preclinical data showing its atomic layer deposition (ALD) platform PharmaShell® improves the pharmacokinetic profile of monthly semaglutide injections, potentially mitigating side effects of GLP-1 drugs.",
      "entities": {
        "companies": [
          "Nanexa"
        ],
        "molecules": [
          "semaglutide"
        ],
        "technologies": [
          "atomic layer deposition",
          "PharmaShell®"
        ],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": [],
        "dosing_intervals": [
          "monthly"
        ]
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-27",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 90,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "core_technologies: atomic layer deposition",
          "pure_player_companies: Nanexa",
          "trademarks: PharmaShell®"
        ],
        "medium": [
          "technology_families: drug delivery",
          "dosing_intervals: monthly"
        ],
        "weak": [
          "molecules: semaglutide"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "core_technologies": 20,
          "pure_player_companies": 15,
          "trademarks": 10,
          "dosing_intervals": 5
        },
        "recency_boost": 5,
        "confidence_penalty": 0,
        "total": 90
      },
      "reasoning": "The item mentions Nanexa, a pure-play LAI company, along with its core ALD technology PharmaShell® and a long-acting monthly dosing interval for semaglutide. Multiple strong and medium signals indicate high relevance to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {},
      "final_score": 2.3,
      "effective_date": "2026-01-27",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.92,
        "weighted_base": 0.28,
        "total_bonus": 2.0,
        "total_penalty": 0,
        "raw_score": 2.28,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercebiotech_20260204_a066b1",
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/abbott-hit-quality-violations-fda-over-freestyle-libre-cgm-products\" hreflang=\"en\">FDA demands better response from Abbott over Libre inspection violations </a>",
    "content": "Abbott has been hit with a slew of complaints from the FDA in a warning letter related to its continuous glucose monitor franchise, FreeStyle Libre.",
    "url": "https://www.fiercebiotech.com/medtech/abbott-hit-quality-violations-fda-over-freestyle-libre-cgm-products",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:46.719869",
    "language": "en",
    "content_hash": "sha256:ca6afd6ac30f62f24088a84d0eb6ba246342e0718ca2446b13fff1f70a55a564",
    "metadata": {
      "author": "Ben Adams",
      "tags": [],
      "word_count": 25
    },
    "normalized_at": "2026-02-04T16:25:09.663131Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.9,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The FDA has issued a warning letter to Abbott regarding quality violations related to its FreeStyle Libre continuous glucose monitoring products.",
      "entities": {
        "companies": [
          "Abbott"
        ],
        "molecules": [],
        "technologies": [
          "continuous glucose monitor"
        ],
        "trademarks": [
          "FreeStyle Libre"
        ],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.9,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "pure_player_company: Abbott",
          "trademark: FreeStyle Libre"
        ],
        "medium": [
          "technology_family: continuous glucose monitor"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "pure_player_company": 15,
          "trademark": 15
        },
        "recency_boost": 10,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "The item mentions the pure player company Abbott and its trademark FreeStyle Libre continuous glucose monitoring products. The regulatory event is highly relevant to the LAI domain. Recent date further boosts the score."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5,
        "regulatory_tech_combo": 1.0
      },
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 1.7,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.18,
        "total_bonus": 3.5,
        "total_penalty": -2.0,
        "raw_score": 1.67,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260203_ce7939",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo",
    "content": "The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...",
    "url": "https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-04T16:23:49.403328",
    "language": "en",
    "content_hash": "sha256:6a666e59d3cba56f86d243748a56bf06a589e1b2039bf9b19cc95b1fc03f4b6f",
    "metadata": {
      "author": "Anna Brown",
      "tags": [
        "Pharma",
        "FDA+"
      ],
      "word_count": 32
    },
    "normalized_at": "2026-02-04T16:26:00.035062Z",
    "effective_date": "2023-05-26",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-26",
      "bedrock_confidence": 0.8,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe.",
      "entities": {
        "companies": [
          "AstraZeneca"
        ],
        "molecules": [
          "Saphnelo"
        ],
        "technologies": [],
        "trademarks": [
          "Saphnelo"
        ],
        "indications": [
          "systemic lupus erythematosus (SLE)"
        ],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-26",
      "date_confidence": 0.8,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 70,
      "confidence": "medium",
      "signals_detected": {
        "strong": [
          "trademarks: Saphnelo"
        ],
        "medium": [
          "hybrid_company: AstraZeneca"
        ],
        "weak": [
          "molecule: Saphnelo",
          "indication: systemic lupus erythematosus (SLE)"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "trademark": 20,
          "hybrid_company": 10,
          "molecule": 5,
          "indication": 5
        },
        "recency_boost": 10,
        "confidence_penalty": -30,
        "total": 70
      },
      "reasoning": "The item mentions the trademark Saphnelo and hybrid company AstraZeneca, along with the molecule and indication. However, there are no strong LAI technology signals, so confidence is medium. The recent date provides a recency boost."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5
      },
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 0.7,
      "effective_date": "2023-05-26",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.18,
        "total_bonus": 2.5,
        "total_penalty": -2.0,
        "raw_score": 0.67,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercepharma_20260204_895527",
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo\" hreflang=\"en\">FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision</a>",
    "content": "AstraZeneca will have to negotiate what appears to be a minor speed bump in order to gain clearance in the U.S. for its subcutaneous version of lupus treatment Saphnelo. The FDA has rejected AZ's application that would allow patients to self-administer the monoclonal antibody in a prefilled pen. The advancement would give patients a convenient alternative to traveling to a doctor's office for infusions every four weeks.",
    "url": "https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:54.684389",
    "language": "en",
    "content_hash": "sha256:33a946e7564353feada01861918af316efca1c5d65f2b7e76d5a1a9b0000d994",
    "metadata": {
      "author": "Kevin Dunleavy",
      "tags": [],
      "word_count": 67
    },
    "normalized_at": "2026-02-04T16:26:44.254877Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.9,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The FDA has rejected AstraZeneca's application for a subcutaneous version of its lupus treatment Saphnelo, which would allow patients to self-administer the drug using a prefilled pen instead of receiving infusions every four weeks. However, AstraZeneca expects a quick turnaround for a new approval decision.",
      "entities": {
        "companies": [
          "AstraZeneca"
        ],
        "molecules": [
          "Saphnelo"
        ],
        "technologies": [],
        "trademarks": [
          "Saphnelo"
        ],
        "indications": [
          "lupus"
        ],
        "dosing_intervals": [
          "every four weeks"
        ]
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.9,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 75,
      "confidence": "medium",
      "signals_detected": {
        "strong": [
          "trademark: Saphnelo"
        ],
        "medium": [
          "dosing_interval: every four weeks",
          "hybrid_company: AstraZeneca"
        ],
        "weak": [
          "molecule: Saphnelo",
          "route: subcutaneous"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "trademark": 20,
          "dosing_interval": 10,
          "hybrid_company": 5
        },
        "recency_boost": 10,
        "confidence_penalty": -20,
        "total": 75
      },
      "reasoning": "The item mentions the trademark Saphnelo, a long-acting dosing interval, and the hybrid company AstraZeneca. The subcutaneous route and molecule Saphnelo are weak signals. While no strong core LAI signals are present, the combination of medium and weak signals suggests a medium confidence LAI match. The recent date provides a recency boost."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5
      },
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 0.7,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.18,
        "total_bonus": 2.5,
        "total_penalty": -2.0,
        "raw_score": 0.67,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260204_e3d7ad",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "content": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28Essi Nevo2025-08-15T11:33:54+02:00August 15th, 2025|Read More",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:44.573643",
    "language": "en",
    "content_hash": "sha256:9362998c5af4ef533152f4c2d2f7f2a5a831f17fb5c84d2e9918492eabf312d7",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 13
    },
    "normalized_at": "2026-02-04T16:24:51.859534Z",
    "effective_date": "2025-08-15",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-08-15",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The text mentions an event titled 'Partnership Opportunities in Drug Delivery 2025' taking place in Boston on October 27-28. No other specific details about partnerships, companies, or technologies are provided.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2025-08-15",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The normalized item does not contain any signals related to long-acting injectable technologies, companies, products or indications. It only mentions a generic partnership event with no relevant details. Therefore, it is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0
      },
      "penalties": {
        "old_penalty": -1.0,
        "no_entities_penalty": -2.0
      },
      "final_score": 0.3,
      "effective_date": "2025-08-15",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.65,
        "weighted_base": 0.26,
        "total_bonus": 3.0,
        "total_penalty": -3.0,
        "raw_score": 0.26,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260204_795bf1",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "GSK’s new CEO eyes more dealmaking, intense pipeline inspection",
    "content": "GSK CEO Luke Miels laid out the drugmaker’s vision for how it will meet its 2031 sales forecast and address the upcoming patent cliff for its blockbuster HIV drug dolutegravir.\n\n “We need ...",
    "url": "https://endpoints.news/gsks-new-ceo-eyes-more-dealmaking-intense-pipeline-inspection/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:49.403328",
    "language": "en",
    "content_hash": "sha256:b5409101ca48b5e1d72aaae0ab517855741966919f14ead21c5ce2a9751cdcc9",
    "metadata": {
      "author": "Reynald Castañeda",
      "tags": [
        "R&D",
        "Pharma"
      ],
      "word_count": 33
    },
    "normalized_at": "2026-02-04T16:25:34.800344Z",
    "effective_date": "2026-02-04",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "GSK's new CEO Luke Miels outlined the drugmaker's strategy to meet its 2031 sales forecast and address the upcoming patent expiration for its blockbuster HIV drug dolutegravir, which involves pursuing more deals and closely evaluating its pipeline.",
      "entities": {
        "companies": [
          "GSK"
        ],
        "molecules": [
          "dolutegravir"
        ],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "HIV"
        ],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 65,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "hybrid_company: GSK"
        ],
        "weak": [
          "molecule: dolutegravir",
          "indication: HIV"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "hybrid_company": 10,
          "molecule": 5
        },
        "recency_boost": 0,
        "confidence_penalty": -25,
        "total": 65
      },
      "reasoning": "GSK is a hybrid pharmaceutical company working on long-acting HIV drugs like dolutegravir. However, no strong LAI signals detected, so medium confidence match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {},
      "final_score": 0.2,
      "effective_date": "2026-02-04",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.25,
        "total_bonus": 0,
        "total_penalty": 0,
        "raw_score": 0.25,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260204_d54a32",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts",
    "content": "Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer's monthly obesity shot. It has also cut a handful of drugs from its pipeline, so it certainly has ...",
    "url": "https://endpoints.news/embattled-novo-nordisk-considers-buying-a-monthly-glp-1-to-bolster-portfolio/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:49.403328",
    "language": "en",
    "content_hash": "sha256:4281dc2cdbf1f553421b84ea19b4850e2a8f76fb005cfe84b6c6bdff68cb47e1",
    "metadata": {
      "author": "Elizabeth Cairns",
      "tags": [
        "R&D",
        "Pharma"
      ],
      "word_count": 36
    },
    "normalized_at": "2026-02-04T16:25:40.496006Z",
    "effective_date": "2026-02-04",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Novo Nordisk is considering acquiring or developing a long-acting GLP-1 drug that could be dosed monthly to compete with Pfizer's monthly obesity shot. The company has also cut some drugs from its pipeline.",
      "entities": {
        "companies": [
          "Novo Nordisk",
          "Pfizer"
        ],
        "molecules": [
          "GLP-1"
        ],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "obesity"
        ],
        "dosing_intervals": [
          "monthly"
        ]
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 70,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "hybrid_company: Novo Nordisk",
          "dosing_interval: monthly"
        ],
        "weak": [
          "molecule: GLP-1"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "hybrid_company": 10,
          "dosing_interval": 10
        },
        "recency_boost": 0,
        "confidence_penalty": -20,
        "total": 70
      },
      "reasoning": "Novo Nordisk is a hybrid company working on long-acting GLP-1 drugs for obesity. Monthly dosing interval mentioned. Medium confidence due to lack of strong signals."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {},
      "final_score": 0.2,
      "effective_date": "2026-02-04",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.25,
        "total_bonus": 0,
        "total_penalty": 0,
        "raw_score": 0.25,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260203_5675a6",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Daiichi ends work on an ADC; Layoffs at GSK's R&D unit",
    "content": "Plus, news about Acadia Pharmaceuticals, Eli Lilly, PepLib Biotech, MeiraGTx, ZipBio, Santé Ventures, Adlai Nortye, NMD Pharma, Eton Pharmaceuticals, vTv Therapeutics and Newsoara:\n\n  ✂️ Daiichi Sankyo culls next-gen ADC: Citing a strategic portfolio review ...",
    "url": "https://endpoints.news/daiichi-ends-work-on-an-adc-layoffs-at-gsks-rd-unit/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-04T16:23:49.403328",
    "language": "en",
    "content_hash": "sha256:dde98b40897c19e70976fc5ab2ad76dacba28d3c1a81da55057d6edf57b4e250",
    "metadata": {
      "author": "ENDPOINTS",
      "tags": [
        "News Briefing"
      ],
      "word_count": 35
    },
    "normalized_at": "2026-02-04T16:25:47.449710Z",
    "effective_date": "2026-02-03",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Daiichi Sankyo has ended work on a next-generation antibody-drug conjugate (ADC) after a strategic portfolio review. GSK has laid off employees in its R&D unit.",
      "entities": {
        "companies": [
          "Daiichi Sankyo",
          "GSK",
          "Acadia Pharmaceuticals",
          "Eli Lilly",
          "PepLib Biotech",
          "MeiraGTx",
          "ZipBio",
          "Santé Ventures",
          "Adlai Nortye",
          "NMD Pharma",
          "Eton Pharmaceuticals",
          "vTv Therapeutics",
          "Newsoara"
        ],
        "molecules": [],
        "technologies": [
          "ADC"
        ],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 70,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "technology_families: ADC"
        ],
        "weak": [
          "molecules"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "technology_families": 15,
          "companies": 5
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 70
      },
      "reasoning": "The item mentions antibody-drug conjugate (ADC) technology, which is a medium signal for LAI relevance. The companies Daiichi Sankyo and GSK are also detected. While there are no strong signals, the ADC technology and presence of pharma companies make this a medium confidence match for the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {},
      "final_score": 0.2,
      "effective_date": "2026-02-03",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.25,
        "total_bonus": 0,
        "total_penalty": 0,
        "raw_score": 0.25,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercepharma_20260204_e59dfb",
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/rising-stars-barbara-leal-lives-and-works-mantra-humans-first-professionals-second\" hreflang=\"en\">Rising Stars: emagineHealth's Barbara Leal lives and works by the mantra of ‘humans first, professionals second’</a>",
    "content": "In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Leal explained how healthcare and pharma marketing combines the “best of both worlds” for her.",
    "url": "https://www.fiercepharma.com/marketing/rising-stars-barbara-leal-lives-and-works-mantra-humans-first-professionals-second",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:54.684389",
    "language": "en",
    "content_hash": "sha256:5456d2facfce1f5090b0b3148fc1007544a2af201ad1416575463293d7bb792d",
    "metadata": {
      "author": "John Newton",
      "tags": [],
      "word_count": 25
    },
    "normalized_at": "2026-02-04T16:26:36.858358Z",
    "effective_date": "2026-02-04",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The article is a Q&A with Barbara Leal of emagineHealth, discussing her approach to healthcare and pharma marketing. No specific companies, molecules, technologies, or dosing intervals are mentioned.",
      "entities": {
        "companies": [
          "emagineHealth"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No strong, medium or weak signals detected related to LAI domain. The item is about a marketing professional's approach and does not mention any specific companies, molecules, technologies or dosing intervals relevant to LAI."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {},
      "final_score": 0.2,
      "effective_date": "2026-02-04",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.25,
        "total_bonus": 0,
        "total_penalty": 0,
        "raw_score": 0.25,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercebiotech_20260204_8f7e97",
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/novos-cagrisema-tops-semaglutide-ph-3-diabetes-study-still-falls-short-25-weight-loss-goal\" hreflang=\"en\">Novo’s CagriSema tops semaglutide in ph. 3 diabetes study</a>",
    "content": "Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had previously laid out for its next-gen metabolic asset.",
    "url": "https://www.fiercebiotech.com/biotech/novos-cagrisema-tops-semaglutide-ph-3-diabetes-study-still-falls-short-25-weight-loss-goal",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:46.719869",
    "language": "en",
    "content_hash": "sha256:62e100bc2ae918bad3ab843193e112fa727f5ecdc095f45014a7c26b7c928ae2",
    "metadata": {
      "author": "Darren Incorvaia",
      "tags": [],
      "word_count": 39
    },
    "normalized_at": "2026-02-04T16:25:22.844639Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.8,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Novo Nordisk's GLP-1/amylin combo CagriSema outperformed semaglutide in a phase 3 trial for Type 2 diabetes, but fell short of the 25% weight loss goal set by the company.",
      "entities": {
        "companies": [
          "Novo Nordisk"
        ],
        "molecules": [
          "CagriSema",
          "semaglutide"
        ],
        "technologies": [],
        "trademarks": [
          "CagriSema",
          "Ozempic"
        ],
        "indications": [
          "Type 2 diabetes"
        ],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.8,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 75,
      "confidence": "medium",
      "signals_detected": {
        "strong": [
          "pure_player_company: Novo Nordisk"
        ],
        "medium": [
          "trademarks: CagriSema, Ozempic"
        ],
        "weak": [
          "molecules: CagriSema, semaglutide",
          "indication: Type 2 diabetes"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "pure_player_company": 25,
          "trademarks": 10
        },
        "recency_boost": 5,
        "confidence_penalty": -25,
        "total": 75
      },
      "reasoning": "Novo Nordisk is a pure-play LAI company. CagriSema and Ozempic are trademarks mentioned. Clinical trial update for diabetes indication. Medium confidence due to lack of strong technology signals."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 0.1,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.15,
        "total_bonus": 2.0,
        "total_penalty": -2.0,
        "raw_score": 0.15,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260204_aa5561",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026",
    "content": "UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026January 28, 2026January 28, 2026",
    "url": "https://www.medincell.com/wp-content/uploads/2026/01/PR_MDC_TevaQ42025results_EN_28012026_vf.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:58323a1cdefb125396e7beaff04ca98f6f11f926a9ad5fe5eac3cf61347873a8",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 26
    },
    "normalized_at": "2026-02-04T16:24:09.637188Z",
    "effective_date": "2026-01-28",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-28",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The news reports financial results for UZEDY®, with net sales increasing from $117M in 2024 to $191M in 2025, a 63% increase. It also mentions that a submission for OLANZAPINE LAI is expected in the EU in Q2 2026.",
      "entities": {
        "companies": [],
        "molecules": [
          "OLANZAPINE"
        ],
        "technologies": [
          "LAI"
        ],
        "trademarks": [
          "UZEDY®"
        ],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-28",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 90,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "trademark: UZEDY®",
          "core_technology: LAI"
        ],
        "medium": [
          "technology_family: microspheres"
        ],
        "weak": [
          "molecule: OLANZAPINE"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "trademark": 20,
          "core_technology": 25
        },
        "recency_boost": 10,
        "confidence_penalty": 0,
        "total": 90
      },
      "reasoning": "The item mentions the trademark UZEDY® and the core LAI technology, along with microsphere technology family and the molecule olanzapine. Recent date with no exclusions, indicating high confidence LAI relevance."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-01-28",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.95,
        "weighted_base": 0.14,
        "total_bonus": 0,
        "total_penalty": -1.0,
        "raw_score": -0.86,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260204_662f02",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Publication of the 2026 financial calendar",
    "content": "Publication of the 2026 financial calendarJanuary 12, 2026January 12, 2026",
    "url": "https://www.medincell.com/wp-content/uploads/2026/01/MDC_Agenda2026_12012026_EN_vf.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:87aae11e6edc5e0ffed9cc27be20b0ce9a948ff6861602998c7fe882321e4026",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-04T16:24:13.481983Z",
    "effective_date": "2026-01-12",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-12",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The news item announces the publication of the 2026 financial calendar for a company.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-12",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. The item is about publishing a financial calendar, which is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-01-12",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.88,
        "weighted_base": 0.13,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.87,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260204_2b08cd",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)",
    "content": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)December 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:d31f0b2539d43d16674e54130adf76dadd16de4d64da01b46089ef7d05087f56",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 19
    },
    "normalized_at": "2026-02-04T16:24:18.176153Z",
    "effective_date": "2025-12-09",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-12-09",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Medincell published its consolidated financial results for the half-year period from April 1st, 2025 to September 30, 2025.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2025-12-09",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is about a company publishing financial results, which does not contain any signals relevant to the LAI domain. There are no exclusions detected either. Therefore, this item is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-12-09",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.82,
        "weighted_base": 0.12,
        "total_bonus": 0,
        "total_penalty": -1.0,
        "raw_score": -0.88,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260204_63c5d2",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "content": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital GrowthNovember 11, 2025November 11, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:0fd65830bac79a1367fb57ebdb608040c3d60da28c61faceaa909e7a158b29f2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 23
    },
    "normalized_at": "2026-02-04T16:24:35.737988Z",
    "effective_date": "2025-11-11",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-11",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Medincell appointed Dr Grace Kim as Chief Strategy Officer for U.S. Finance to advance the company's growth in the U.S. capital market.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-11",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is about a corporate move of appointing a Chief Strategy Officer. It does not contain any signals related to long-acting injectables (LAI) technologies, products or companies. Therefore, it is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "aging_penalty": -0.5
      },
      "final_score": 0,
      "effective_date": "2025-11-11",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.19,
        "total_bonus": 0,
        "total_penalty": -0.5,
        "raw_score": -0.31,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260204_846e38",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "content": "Medincell to Join MSCI World Small Cap Index, a Leading Global BenchmarkNovember 10, 2025November 10, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:42.423349",
    "language": "en",
    "content_hash": "sha256:56a3453e4ee40153ae56677367b25aa29f62e6fdeeba03e4c9c8d2f2706a1923",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 16
    },
    "normalized_at": "2026-02-04T16:24:40.148859Z",
    "effective_date": "2025-11-10",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-10",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Medincell, a biotech company, will be added to the MSCI World Small Cap Index, a leading global benchmark index.",
      "entities": {
        "companies": [
          "Medincell"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-10",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is about a corporate move of a biotech company being added to a stock index. There are no signals related to long-acting injectables or relevant exclusions detected. Therefore, this item is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "aging_penalty": -0.5
      },
      "final_score": 0,
      "effective_date": "2025-11-10",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.19,
        "total_bonus": 0,
        "total_penalty": -0.5,
        "raw_score": -0.31,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260204_ad0afc",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "content": "BIO International Convention 2025 Boston, June 16-19Aleksi Leino2025-06-12T15:59:56+02:00June 12th, 2025|Read More",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:44.573643",
    "language": "en",
    "content_hash": "sha256:57720ff336bac6a3ca5237373c94baaa3eec122461772429e7c57553296abdcf",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2026-02-04T16:24:55.949474Z",
    "effective_date": "2025-06-12",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-06-12",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The BIO International Convention 2025 will be held in Boston from June 16-19, 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": "2025-06-12",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI-relevant signals detected in the item. It appears to be about a general biotech convention, with no specific mentions of long-acting injectables or related technologies."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-06-12",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.05,
        "total_bonus": 0,
        "total_penalty": -5.0,
        "raw_score": -4.95,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260204_dddc9f",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Bio Europe Spring 2025 Milan, March 17-19",
    "content": "Bio Europe Spring 2025 Milan, March 17-19Milla Runsala2025-02-19T12:33:49+02:00February 17th, 2025|Read More",
    "url": "https://www.delsitech.com/bio-europe-spring-2025-milan-march-17-19/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:44.573643",
    "language": "en",
    "content_hash": "sha256:960cdcae688eed2f19c4753685af51b62ae13017e3fbf4bbac02a4822228face",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2026-02-04T16:25:00.072630Z",
    "effective_date": "2025-02-19",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-02-19",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Bio Europe Spring 2025 is an upcoming event scheduled to take place in Milan from March 17-19, 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": "2025-02-19",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No strong, medium or weak signals detected related to long-acting injectables. The item appears to be about a general biotech event with no specific relevance to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-02-19",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.05,
        "total_bonus": 0,
        "total_penalty": -5.0,
        "raw_score": -4.95,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260204_e99236",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "TIDES Asia 2025 Kyoto, February 26-28",
    "content": "TIDES Asia 2025 Kyoto, February 26-28Milla Runsala2025-02-19T12:49:02+02:00February 15th, 2025|Read More",
    "url": "https://www.delsitech.com/tides-asia-2025-kyoto-february-26-28/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:44.573643",
    "language": "fr",
    "content_hash": "sha256:7837e99508bbf82ae906e463ce964af3d7356e0c7525d68b3b8b0fb61c71c383",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-04T16:25:04.316464Z",
    "effective_date": "2025-02-19",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-02-19",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "This is an announcement for the TIDES Asia 2025 conference to be held in Kyoto, Japan from February 26-28, 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": "2025-02-19",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is an announcement for a conference and does not contain any signals related to long-acting injectables (LAI) or exclusions. Therefore, it is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-02-19",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.05,
        "total_bonus": 0,
        "total_penalty": -5.0,
        "raw_score": -4.95,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercebiotech_20260204_9d5827",
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight\" hreflang=\"en\">GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'</a>",
    "content": "Luke Miels had only been at the helm of GSK for 20 days when he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest.",
    "url": "https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:46.719869",
    "language": "en",
    "content_hash": "sha256:9d5aa7ed7b8068babd34b39c535ae0db690148d8abec594c152a782c7e50f191",
    "metadata": {
      "author": "James Waldron",
      "tags": [],
      "word_count": 34
    },
    "normalized_at": "2026-02-04T16:25:15.780325Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.9,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "GSK's new CEO Luke Miels is looking for deals worth $2 billion to $4 billion that are 'hiding in plain sight'. Miels had only been CEO for 20 days when he signed off on his first multibillion-dollar buyout.",
      "entities": {
        "companies": [
          "GSK"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.9,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 60,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "hybrid_company: GSK"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "hybrid_company": 10
        },
        "recency_boost": 10,
        "confidence_penalty": -20,
        "total": 60
      },
      "reasoning": "GSK is a hybrid company involved in both small molecules and biologics/drug delivery technologies. The news is about their corporate strategy for deals, which could potentially involve LAI technologies, but there are no strong signals present. Medium confidence match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 0,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.12,
        "total_bonus": 0,
        "total_penalty": -2.0,
        "raw_score": -1.88,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260204_ec88d7",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "content": "6 November, 2025Nanexa publishes interim report for January-September 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:52.534202",
    "language": "en",
    "content_hash": "sha256:5e92a34fa02feb0c756160060d140bd43be564d228173af1a7475fc55abd2012",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-04T16:26:24.040564Z",
    "effective_date": "2025-11-06",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-06",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Nanexa, a pharmaceutical company, published its interim financial report for the period of January to September 2025.",
      "entities": {
        "companies": [
          "Nanexa"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-06",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is about a financial report from a pharmaceutical company and does not contain any signals related to long-acting injectable technologies or products. It is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "aging_penalty": -0.5,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-11-06",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.11,
        "total_bonus": 0,
        "total_penalty": -1.5,
        "raw_score": -1.39,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260204_e8d104",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "content": "Download attachment",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:52.534202",
    "language": "en",
    "content_hash": "sha256:3d03c0ba4af110790f2466800ad3cb177d90875ff5aca390550800cb8fb5b287",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 2
    },
    "normalized_at": "2026-02-04T16:26:27.972215Z",
    "effective_date": "2026-02-04",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "This news item does not contain any substantive information. It appears to be a placeholder or an error.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The normalized item does not contain any substantive information and appears to be a placeholder or an error. There are no signals detected that would indicate relevance to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-02-04",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.9,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260204_76ad60",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "content": "27 August, 2025Nanexa publishes interim report for January-June 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:52.534202",
    "language": "en",
    "content_hash": "sha256:5ebaa7e082a1cf6d1df5f67bacd000c99e99c281c9cc7c0d2499114067d696b3",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-04T16:26:32.066994Z",
    "effective_date": "2025-08-27",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-08-27",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "Nanexa, a pharmaceutical company, published its interim financial report for the first half of 2025.",
      "entities": {
        "companies": [
          "Nanexa"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2025-08-27",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is about a financial report from a pharmaceutical company and does not contain any signals related to long-acting injectable technologies or products. Therefore, it is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "old_penalty": -1.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-08-27",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.65,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -2.0,
        "raw_score": -1.9,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercepharma_20260204_2d58a7",
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine\" hreflang=\"en\">Sanofi sanctioned by PMCPA over CEO's 'bold claims' about Pfizer RSV vaccine</a>",
    "content": "A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s vaccine program by making “bold claims” about a procurement choice.",
    "url": "https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:54.684389",
    "language": "en",
    "content_hash": "sha256:0b4609d3c59e9437627e0594b3cdfc6d9f6b05b463467bbf8ca2334c142f44f1",
    "metadata": {
      "author": "Nick Paul Taylor",
      "tags": [],
      "word_count": 29
    },
    "normalized_at": "2026-02-04T16:26:50.571158Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.8,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government's vaccine program by making 'bold claims' about a procurement choice related to Pfizer's RSV vaccine.",
      "entities": {
        "companies": [
          "Sanofi",
          "Pfizer"
        ],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "RSV"
        ],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.8,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 70,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "hybrid_company: Sanofi",
          "hybrid_company: Pfizer"
        ],
        "weak": [
          "indication: RSV"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "hybrid_company": 15,
          "indication": 5
        },
        "recency_boost": 10,
        "confidence_penalty": -10,
        "total": 70
      },
      "reasoning": "The item mentions two major pharmaceutical companies, Sanofi and Pfizer, in relation to an RSV vaccine. While these are hybrid companies and not pure LAI players, their involvement in an RSV vaccine program is relevant to the LAI domain. The recent date also boosts the score. However, the lack of strong signals like core technologies or trademarks reduces the confidence level to medium."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 0,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.12,
        "total_bonus": 0,
        "total_penalty": -2.0,
        "raw_score": -1.88,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercepharma_20260204_e86749",
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/why-human-expertise-still-matters-ai-driven-med-comms\" hreflang=\"en\">Why human expertise still matters in AI-driven med comms</a>",
    "content": "RTI Health Solutions experts explain how AI can help medical communications without replacing rigor, judgment or trust.",
    "url": "https://www.fiercepharma.com/sponsored/why-human-expertise-still-matters-ai-driven-med-comms",
    "published_at": "2026-02-04",
    "ingested_at": "2026-02-04T16:23:54.684389",
    "language": "en",
    "content_hash": "sha256:99a606c9ac3663f315d153a03429d770f20938f38a99a66a8792312343dc406f",
    "metadata": {
      "author": "Questex Partner",
      "tags": [],
      "word_count": 17
    },
    "normalized_at": "2026-02-04T16:26:55.869418Z",
    "effective_date": "2026-02-04",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-04"
    },
    "normalized_content": {
      "summary": "The article discusses the importance of human expertise in AI-driven medical communications, explaining how AI can assist without replacing rigor, judgment or trust.",
      "entities": {
        "companies": [
          "RTI Health Solutions"
        ],
        "molecules": [],
        "technologies": [
          "AI"
        ],
        "trademarks": [],
        "indications": [],
        "dosing_intervals": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 70,
      "confidence": "medium",
      "signals_detected": {
        "strong": [
          "core_technologies: AI"
        ],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "core_technologies": 20
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 70
      },
      "reasoning": "The item discusses the role of AI in medical communications, which is a core technology for the LAI domain. However, there are no specific LAI-related entities mentioned, so the confidence is medium."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-02-04",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -1.0,
        "raw_score": -0.9,
        "scoring_mode": "balanced"
      }
    }
  }
]